Regeneron seeks to edge Roche out of DME space

Share this article:
Eylea outduels Lucentis for physician mindshare, survey shows
Eylea outduels Lucentis for physician mindshare, survey shows

A year after its eye drug Lucentis landed the FDA's approval for diabetic macular edema, Roche's hold on this Eylea-free zone of the market may soon be ending. Regeneron, Eylea's manufacturer, said Tuesday that it expects to submit an NDA for this very same indication to the FDA this year, while its European marketing partner, Bayer, is on track to do the same abroad.

This would mean more than a me-too in the diabetic macular edema (DME) space. As noted by Forbes, Lucentis has a downside in that its label has a fatality warning. Eylea's does not, and that could give the Regeneron drug an edge if it too gets approved for use in DME.

It's not the first threat to Lucentis' hold on the eye market. The wet macular-degeneration drug saw immediate competition from off-label use of Genentech's Avastin, then from macular-degeneration newcomer Eylea.

DME is linked to blurry vision and even blindness, and estimates say it affects about 560,000 Americans.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.